Atyr Pharma Stock Total Debt
ATyr Pharma fundamentals help investors to digest information that contributes to ATyr Pharma's financial success or failures. It also enables traders to predict the movement of ATyr Stock. The fundamental analysis module provides a way to measure ATyr Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ATyr Pharma stock.
ATyr |
ATyr Pharma Company Total Debt Analysis
ATyr Pharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current ATyr Pharma Total Debt | 15.1 M |
Most of ATyr Pharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ATyr Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, ATyr Pharma has a Total Debt of 15.1 M. This is 99.45% lower than that of the Biotechnology sector and 95.35% lower than that of the Health Care industry. The total debt for all United States stocks is 99.72% higher than that of the company.
ATyr Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ATyr Pharma's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ATyr Pharma could also be used in its relative valuation, which is a method of valuing ATyr Pharma by comparing valuation metrics of similar companies.ATyr Pharma is currently under evaluation in total debt category among its peers.
ATyr Fundamentals
| Return On Equity | -0.56 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (70.79) % | |||
| Current Valuation | 55.05 M | |||
| Shares Outstanding | 69.01 M | |||
| Shares Owned By Insiders | 2.61 % | |||
| Shares Owned By Institutions | 61.69 % | |||
| Number Of Shares Shorted | 343.41 K | |||
| Price To Earning | (2.19) X | |||
| Price To Book | 1.30 X | |||
| Price To Sales | 334.89 X | |||
| Revenue | 353 K | |||
| Gross Profit | (32.42 M) | |||
| EBITDA | (52.18 M) | |||
| Net Income | (50.39 M) | |||
| Cash And Equivalents | 88.55 M | |||
| Cash Per Share | 3.09 X | |||
| Total Debt | 15.1 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 10.08 X | |||
| Book Value Per Share | 1.24 X | |||
| Cash Flow From Operations | (33.22 M) | |||
| Short Ratio | 0.60 X | |||
| Earnings Per Share | (0.88) X | |||
| Target Price | 24.6 | |||
| Number Of Employees | 56 | |||
| Beta | 1.19 | |||
| Market Capitalization | 131.12 M | |||
| Total Asset | 122.07 M | |||
| Retained Earnings | (468.02 M) | |||
| Working Capital | 86.58 M | |||
| Current Asset | 97.95 M | |||
| Current Liabilities | 12.15 M | |||
| Net Asset | 122.07 M |
About ATyr Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ATyr Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ATyr Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ATyr Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in ATyr Stock
If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |